Related Experiment Video
Updated: Mar 28, 2026
Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
Published on: October 19, 2013
[Effect of puerarin on hypoxia induced proliferation of PASMCs by regulating reactive oxygen]
Abstract:
To discuss the effect of puerarin (Pue) on the proliferation of hypoxia-induced pulmonary artery smooth muscle cells (PASMCs) and discuss whether its mechanism is achieved by regulating reactive oxygen. PASMCs of primarily cultured rats (2-5 generations) were selected in the experiment. MTT, Western blot, FCM and DCFH-DA were used to observe Pue's effect the proliferation of PASMCs. The Western blot was adopted to detect whether ROS participated in Pue's effect in inhibiting PASMC proliferation. The PASMCs were divided into five groups: the normoxia group, the hypoxia group, the hypoxia + Pue group, the hypoxia + Pue + Rotenone group and the hypoxia + Rotenone group, with Rotenone as the ROS blocker. According to the results, under the conditions of normoxia, Pue had no effect on the PASMC proliferation; But, under the conditions of hypoxia, it could inhibit the PASMC proliferation; Under the conditions of normoxia and hypoxia, Pue had no effect on the expression of the tumor necrosis factor-α (TNF-α) among PASMCs, could down-regulate the expression of hypoxia-induced cell cycle protein Cyclin A and proliferative nuclear antigen (PCNA). DCFH-DA proved Pue could reverse ROS rise caused by hypoxia. Both Rotenone and Pue could inhibit the up-regulated expressions of HIF-1α, Cyclin A, PCNA caused by anoxia, with a synergistic effect. The results suggested that Pue could inhibit the hypoxia-induced PASMC proliferation. Its mechanism may be achieved by regulating ROS.
Insights
Puerarin (Pue) inhibits the proliferation of pulmonary artery smooth muscle cells (PASMCs) under hypoxic conditions. This effect is mediated by regulating reactive oxygen species (ROS), suggesting a potential therapeutic mechanism.
Area of Science:
- Cardiovascular Research
- Cell Biology
- Pharmacology
Background:
- Pulmonary artery smooth muscle cell (PASMC) proliferation is a key factor in pulmonary hypertension.
- Hypoxia is a major trigger for PASMC proliferation.
- Understanding the molecular mechanisms regulating PASMC proliferation is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the effect of puerarin (Pue) on hypoxia-induced PASMC proliferation.
- To elucidate the role of reactive oxygen species (ROS) in the mechanism of Pue's action.
Main Methods:
- Primary rat PASMCs were cultured and subjected to normoxic and hypoxic conditions.
- Cell proliferation was assessed using MTT assays.
- Western blot analysis was employed to detect protein expression levels (e.g., Cyclin A, PCNA, HIF-1α).
- Reactive oxygen species (ROS) levels were measured using DCFH-DA.
- Rotenone was used as a ROS blocker to investigate its involvement.
Main Results:
- Puerarin inhibited PASMC proliferation under hypoxic conditions but not under normoxic conditions.
- Puerarin down-regulated the expression of hypoxia-induced cell cycle proteins Cyclin A and PCNA.
- Puerarin reversed the hypoxia-induced increase in ROS levels.
- Puerarin and Rotenone exhibited a synergistic inhibitory effect on hypoxia-induced HIF-1α, Cyclin A, and PCNA expression.
Conclusions:
- Puerarin effectively inhibits hypoxia-induced proliferation of PASMCs.
- The mechanism of puerarin involves the regulation of reactive oxygen species (ROS).
- Puerarin shows potential as a therapeutic agent for conditions involving PASMC proliferation, such as pulmonary hypertension.
More Related Videos
08:08Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
13:32Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices
Published on: January 14, 2014
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:24Regulation of Angiogenesis and Blood Supply
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...